WG
IONS icon

Winton Group’s Ionis Pharmaceuticals IONS Stock Holding History

Winton Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,532
Closed -$8M – 1336
2026
Q1 		$8M Buy
+106,532
New +$8.41M 0.28% 73
2022
Q3 		– Sell
-42,634
Closed -$1.58M – 1013
2022
Q2 		$1.58M Buy
+42,634
New +$1.61M 0.08% 343
2021
Q1 		– Sell
-7,744
Closed -$438K – 1408
2020
Q4 		$438K Sell
7,744
-108,007
-93% -$5.38M 0.03% 857
2020
Q3 		$5.49M Sell
115,751
-8,818
-7% -$490K 0.18% 100
2020
Q2 		$7.34M Buy
124,569
+42,209
+51% +$2.35M 0.19% 96
2020
Q1 		$3.89M Sell
82,360
-39,504
-32% -$2.2M 0.1% 341
2019
Q4 		$7.36M Buy
121,864
+94,340
+343% +$5.62M 0.1% 338
2019
Q3 		$1.65M Buy
27,524
+20,286
+280% +$1.32M 0.02% 642
2019
Q2 		$465K Buy
+7,238
New +$512K 0.01% 703

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Winton Group's IONS Position: Q2 2026 in Review

Winton Group sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 106,532 shares — an estimated $8M sold.

Winton Group first reported a position in IONS in Q2 2019 and held it in 9 quarters. The position peaked at $8M in Q1 2026. 512 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Winton Group reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 106,532 Ionis Pharmaceuticals shares in Q2 2026, an estimated $8M.
  • Winton Group first reported a position in Ionis Pharmaceuticals in Q2 2019 and held it in 9 quarters.
  • Winton Group's Ionis Pharmaceuticals position peaked at $8M in Q1 2026.
  • 512 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.